37461 |
Oncology |
Osimertinib in central nervous system progressive EGFR-mutant lung can... |
ANN ONCOL 2020 10.1016/j.annonc.2020.08.2234 |
안명주 |
2020 |
37460 |
Oncology; Respiratory System |
Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NS... |
J THORAC ONCOL 2020 10.1016/j.jtho.2020.06.018 |
안명주 |
2020 |
37459 |
Oncology; Respiratory System |
Molecular Testing in Lung Cancer Still Big Gap in Implementation for R... |
J THORAC ONCOL 2020 10.1016/j.jtho.2020.06.006 |
안명주 |
2020 |
37458 |
Pharmacology & Pharmacy |
Evaluating entrectinib as a treatment option for non-small cell lung c... |
EXPERT OPIN PHARMACO 2020 10.1080/14656566.2020.1798932 |
안명주 |
2020 |
37457 |
Oncology |
EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell L... |
CANCER RES TREAT 2020 10.4143/crt.2020.278 |
안명주 |
2020 |
37456 |
Oncology |
Clinical outcomes of immune checkpoint inhibitors for patients with re... |
BMC CANCER 2020 10.1186/s12885-020-07214-4 |
안명주 |
2020 |
37455 |
Respiratory System |
Are there any ethnic differences in the efficacy and safety of immune ... |
J THORAC DIS 2020 10.21037/jtd.2019.08.29 |
안명주 |
2020 |
37454 |
Oncology |
A phase II, multicenter, two cohort study of 160 mg osimertinib in EGF... |
ANN ONCOL 2020 10.1016/j.annonc.2020.06.017 |
안명주 |
2020 |
37453 |
Cardiac & Cardiovascular Systems; Respiratory System; Surgery |
Utility of positron emission-computed tomography for predicting pathol... |
EUR J CARDIO-THORAC 2020 10.1093/ejcts/ezaa181 |
안명주 |
2020 |
37452 |
Oncology; Respiratory System |
Treatment Guidance for Patients With Lung Cancer During the Coronaviru... |
J THORAC ONCOL 2020 10.1016/j.jtho.2020.05.001 |
안명주 |
2020 |